|
1
|
Bhattacharya A, Roy R, Snijders AM,
Hamilton G, Paquette J, Tokuyasu T, Bengtsson H, Jordan RCK, Olshen
AB, Pinkel D, et al: Two distinct routes to oral cancer differing
in genome instability and risk for cervical node metastasis. Clin
Cancer Res. 17:7024–7034. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlito A, Rinaldo A, Robbins KT, Leemans
CR, Shah JP, Shaha AR, Andersen PE, Kowalski LP, Pellitteri PK,
Clayman GL, et al: Changing concepts in the surgical management of
the cervical node metastasis. Oral Oncol. 39:429–435. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greenberg JS, El Naggar AK, Mo V, Roberts
D and Myers JN: Disparity in pathologic and clinical lymph node
staging in oral tongue carcinoma. Implication for therapeutic
decision making. Cancer. 98:508–515. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shingaki S, Takada M, Sasai K, Bibi R,
Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis
on the pattern of failure and survival in oral carcinomas. Am J
Surg. 185:278–284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Woolgar JA, Rogers SN, Lowe D, Brown JS
and Vaughan ED: Cervical lymph node metastasis in oral cancer: The
importance of even microscopic extracapsular spread. Oral Oncol.
39:130–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wikner J, Grobe A, Pantel K and Riethdorf
S: Squamous cell carcinoma of the oral cavity and circulating
tumour cells. World J Clin Oncol. 5:114–124. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhuvarahamurthy V, Kristiansen GO,
Johannsen M, Loening SA, Schnorr D, Jung K and Staack A: In situ
gene expression and localization of metalloproteinases MMP1, MMP2,
MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal
cell carcinoma. ; Oncol Rep. 15:1379–1384. 2006.PubMed/NCBI
|
|
8
|
Kusukawa J, Sasaguri Y, Shima I, Kameyama
T and Morimatsu M: Expression of matrix metalloproteinase-2 related
to lymph node metastasis of oral squamous cell carcinoma. A
clinicopathologic study. Am J Clin Pathol. 99:18–23. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Imai K, Ohuchi E, Aoki T, Nomura H, Fujii
Y, Sato H, Seiki M and Okada Y: Membrane-type matrix
metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a
complex with tissue inhibitor of metalloproteinases 2. Cancer Res.
56:2707–2710. 1996.PubMed/NCBI
|
|
10
|
Strongin AY, Collier I, Bannikov G, Marmer
BL, Grant GA and Goldberg GI: Mechanism of cell surface activation
of 72-kDa type IV collagenase Isolation of the activated form of
the membrane metalloprotease. J Biol Chem. 270:5331–5338. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brodersen P and Voinnet O: Revisiting the
principles of microRNA target recognition and mode of action. Nat
Rev Mol Cell Biol. 10:141–148. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukumoto I, Koshizuka K, Hanazawa T,
Kikkawa N, Matsushita R, Kurozumi A, Kato M, Okato A, Okamoto Y and
Seki N: The tumor-suppressive microRNA-23b/27b cluster regulates
the MET oncogene in oral squamous cell carcinoma. Int J Oncol.
49:1119–1129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukumoto I, Hanazawa T, Kinoshita T,
Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida
H, Nakagawa M, et al: MicroRNA expression signature of oral
squamous cell carcinoma: Functional role of microRNA-26a/b in the
modulation of novel cancer pathways. Br J Cancer. 112:891–900.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baba O, Hasegawa S, Nagai H, Uchida F,
Yamatoji M, Kanno NI, Yamagata K, Sakai S, Yanagawa T and Bukawa H:
MicroRNA-155-5p is associated with oral squamous cell carcinoma
metastasis and poor prognosis. J Oral Pathol. 45:248–255. 2016.
View Article : Google Scholar
|
|
15
|
He S, Lai R, Chen D, Yan W, Zhang Z, Liu
Z, Ding X and Chen Y: Downregulation of miR-221 inhibits cell
migration and invasion through targeting methyl-CpG binding domain
protein 2 in human oral squamous cell carcinoma cells. BioMed Res
Int. 2015:7516722015. View Article : Google Scholar
|
|
16
|
Elgamal OA, Park JK, Gusev Y,
Azevedo-Pouly AC, Jiang J, Roopra A and Schmittgen TD: Tumor
suppressive function of mir-205 in breast cancer is linked to HMGB3
regulation. PLoS One. 8:e764022013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iorio MV, Casalini P, Piovan C, Di Leva G,
Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E:
microRNA-205 regulates HER3 in human breast cancer. Cancer Res.
69:2195–2200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Majid S, Dar AA, Saini S, Yamamura S,
Hirata H, Tanaka Y, Deng G and Dahiya R: MicroRNA-205-directed
transcriptional activation of tumor suppressor genes in prostate
cancer. Cancer. 116:5637–5649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsushima K, Isomoto H, Yamaguchi N,
Inoue N, Machida H, Nakayama T, Hayashi T, Kunizaki M, Hidaka S,
Nagayasu T, et al: miRNA-205 modulates cellular invasion and
migration via regulating zinc finger E-box binding homeobox 2
expression in esophageal squamous cell carcinoma cells. J Transl
Med. 9:302011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang G, Wang L, Sun S, Wu J and Wang Q:
Quantitative measurement of serum microRNA-21 expression in
relation to breast cancer metastasis in Chinese females. Ann Lab
Med. 35:226–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei J, Zhang L, Li J, Zhu S, Tai M, Mason
CW, Chapman JA, Reynolds EA, Weiner CP and Zhou HH: MicroRNA-205
promotes cell invasion by repressing TCF21 in human ovarian cancer.
J Ovarian Res. 10:332017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kinoshita T, Nohata N, Hanazawa T, Kikkawa
N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto
Y, et al: Tumour-suppressive microRNA-29s inhibit cancer cell
migration and invasion by targeting laminin-integrin signalling in
head and neck squamous cell carcinoma. Br J Cancer. 109:2636–2645.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee GY, Kenny PA, Lee EH and Bissell MJ:
Three-dimensional culture models of normal and malignant breast
epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakr M, Takino T, Sabit H, Nakada M, Li Z
and Sato H: miR-150 5p and miR-133a suppress glioma cell
proliferation and migration through targeting membrane-type-1
matrix metalloproteinase. Gene. 587:155–162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W,
Li L, Zhang W, Shi S, Song Y, et al: MicroRNA-29c functions as a
tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol
Cancer. 16:502017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang JK, Li YS, Zhang CD and Dai DQ:
Up-regulation of CRKL by microRNA-335 méthylation is associated
with poor prognosis in gastric cancer. Cancer Cell Int. 17:282017.
View Article : Google Scholar
|
|
29
|
Chen Z, Tang ZY, He Y, Liu LF, Li DJ and
Chen X: miRNA-205 is a candidate tumor suppressor that targets ZEB2
in renal cell carcinoma. Oncol Res Treat. 37:658–664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu H, Zhu S and Mo YY: Suppression of cell
growth and invasion by miR-205 in breast cancer. Cell Res.
19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang N, Li Q, Feng NH, Cheng G, Guan ZL,
Wang Y, Qin C, Yin CJ and Hua LX: miR-205 is frequently
downregulated in prostate cancer and acts as a tumor suppressor by
inhibiting tumor growth. Asian J Androl. 15:735–741. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIPl. Nat Cell Biol. 10:593–601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q
and Tao R: MicroRNA-205 functions as a tumor suppressor in human
glioblastoma cells by targeting VEGF-A. Oncol Rep. 27:1200–1206.
2012. View Article : Google Scholar
|
|
34
|
Adachi R, Horiuchi S, Sakurazawa Y,
Hasegawa T, Sato K and Sakamaki T: ErbB2 down-regulates
microRNA-205 in breast cancer. Biochem Biophys Res Commun.
411:804–808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H and Fan Q: MicroRNA-205 inhibits
the proliferation and invasion of breast cancer by regulating AMOT
expression. Oncol Rep. 34:2163–2170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pang H and Yue X: miR-205 serves as a
prognostic factor and suppresses proliferation and invasion by
targeting insulin-like growth factor receptor 1 in human cervical
cancer. Tumour Biol. 39:10104283177013082017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Childs G, Fazzari M, Kung G, Kawachi N,
Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV,
Prystowsky MB, et al: Low-level expression of microRNAs let-7d and
miR-205 are prognostic markers of head and neck squamous cell
carcinoma. Am J Pathol. 174:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grignon DJ, Sakr W, Toth M, Ravery V,
Angulo J, Shamsa F, Pontes JE, Crissman JC and Fridman R: High
levels of tissue inhibitor of metalloproteinase-2 (TIMP-2)
expression are associated with poor outcome in invasive bladder
cancer. Cancer Res. 56:1654–1659. 1996.PubMed/NCBI
|
|
40
|
Ree AH, Florenes VA, Berg JP, Maelandsmo
GM, Nesland JM and Fodstad O: High levels of messenger RNAs for
tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in
primary breast carcinomas are associated with development of
distant metastases. Clin Cancer Res. 3:1623–1628. 1997.
|
|
41
|
Ondruschka C, Buhtz P, Motsch C, Freigang
B, Schneider-Stock R, Roessner A and Boltze C: Prognostic value of
MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive
front in advanced head and neck squamous cell carcinomas. Pathol
Res Pract. 198:509–515. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoshizaki T, Maruyama Y, Sato H and
Furukawa M: Expression of tissue inhibitor of matrix
metalloproteinase-2 correlates with activation of matrix
metalloproteinase-2 and predicts poor prognosis in tongue squamous
cell carcinoma. Int J Cancer. 95:44–50. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Katayama A, Bandoh N, Kishibe K, Takahara
M, Ogino T, Nonaka S and Harabuchi Y: Expressions of matrix
metalloproteinases in early-stage oral squamous cell carcinoma as
predictive indicators for tumor metastases and prognosis. Clin
Cancer Res. 10:634–640. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sato H, Takino T, Kinoshita T, Imai K,
Okada Y, Stetler Stevenson WG and Seiki M: Cell surface binding and
activation of gelatinase A induced by expression of
membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett.
385:238–240. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hernandez-Barrantes S, Toth M, Bernardo
MM, Yurkova M, Gervasi DC, Raz Y, Sang QA and Fridman R: Binding of
active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP)
to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP
processing and pro-MMP-2 activation. J Biol Chem. 275:12080–12089.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bernardo MM and Fridman R: TIMP-2 (tissue
inhibitor of metalloproteinase-2) regulates MMP-2 (matrix
metalloproteinase-2) activity in the extracellular environment
after pro-MMP-2 activation by MT1 (membrane type 1)-MMP. Biochem J.
374:739–745. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu KV, Jong KA, Rajasekaran AK, Cloughesy
TF and Mischel PS: Upregulation of tissue inhibitor of
metalloproteinases (TIMP)-2 promotes matrix metalloproteinase
(MMP)-2 activation and cell invasion in a human glioblastoma cell
line. Lab Invest. 84:8–20. 2004. View Article : Google Scholar
|
|
48
|
Kudo T, Takino T, Miyamori H, Thompson EW
and Sato H: Substrate choice of membrane-type 1 matrix
metalloproteinase is dictated by tissue inhibitor of
metalloproteinase-2 levels. Cancer Sci. 98:563–568. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nishida Y, Miyamori H, Thompson EW, Takino
T, Endo Y and Sato H: Activation of matrix metalloproteinase-2
(MMP-2) by membrane type 1 matrix metalloproteinase through an
artificial receptor for proMMP-2 generates active MMP-2. Cancer
Res. 68:9096–9104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Caterina JJ, Yamada S, Caterina NC,
Longenecker G, Holmbäck K, Shi J, Yermovsky AE, Engler JA and
Birkedal-Hansen H: Inactivating mutation of the mouse tissue
inhibitor of metalloproteinases-2 (Timp-2) gene alters proMMP-2
activation. J Biol Chem. 275:26416–26422. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Z, Juttermann R and Soloway PD:
TIMP-2 is required for efficient activation of proMMP-2 in vivo. J
Biol Chem. 275:26411–26415. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y
and Nagase H: Plasma membrane-bound tissue inhibitor of
metalloproteinases (TIMP)-2 specifically inhibits matrix
metalloproteinase 2 (gelatinase A) activated on the cell surface. J
Biol Chem. 273:24360–24367. 1998. View Article : Google Scholar : PubMed/NCBI
|
